U.S. flag An official website of the United States government.
Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

i

Analysis of Normal and Malignant Lymphoid Progenitor Cells with Monoclonal Antibodies.

Public Domain


Details

  • Personal Author:
  • Description:
    The cellular and molecular events which were associated with differentiation of normal and malignant human lymphoid progenitor cells have been studied. A panel of monoclonal antibodies has been produced against the human pre-B acute lymphoblastic leukemia cell line NALM-6-M1. These antibodies were designated BA-1, BA-2, and BA- 3. Monoclonal antibody BA-1 binds primarily to cells in the B- lymphocyte lineage. The antigen recognized by BA-1 is lost as B- cells terminally differentiate into plasma cells. About 80 percent of non-T acute lymphoblastic leukemia (ALL), 90 percent of surface Ig+ nonHodgkins lymphomas, and over 95 percent of surface Ig+ chronic lymphocytic leukemias are reactive with BA-1. BA-1 does not bind to natural killer (NK) cells and is nonreactive with hematopoietic stem cells, making this antibody good for the in-vitro removal of residual leukemic cells prior to autologous bone marrow transplantation. Monoclonal antibody BA-2 binds to a small percentage of lymphoid cells in bone marrow, thymus and peripheral blood. BA-2 binds strongly to about 70 percent of ALL, primarily pre-B type, and weakly to about 20 percent T-cell ALL, and 25 percent of AML. BA-2 also shows strong reactivity with a large number of nonhematopoietic tumors including melanomas and neuroblastomas. By not reacting with stem cells it is also a good candidate for in-vitro removal of residual leukemic cells prior to autologous bone marrow transplantation. BA-3 is serologically identical to J-5, a monoclonal antibody identifying the common ALL antigen. [Description provided by NIOSH]
  • Subjects:
  • Keywords:
  • Document Type:
  • Genre:
  • Place as Subject:
  • CIO:
  • Topic:
  • Location:
  • NIOSHTIC Number:
    nn:00187796
  • Citation:
    NIOSH 1982 Apr:623-631
  • Federal Fiscal Year:
    1982
  • Peer Reviewed:
    False
  • Source Full Name:
    Proceedings of the Second NCI/EPA/NIOSH Collaborative Workshop: Progress on Joint Environmental and Occupational Cancer Studies, September 9-11, 1981, Rockville, Maryland
  • Collection(s):
  • Main Document Checksum:
    urn:sha-512:7dc847c09aedf140bc731323e8446b4703641ae07d6ad9e7b7238120dab30b8f7dcaa9b938d34d035f87873a0fe7fec262d5d13dcaf290925445e82b6de3b57d
  • Download URL:
  • File Type:
    Filetype[PDF - 168.02 KB ]
ON THIS PAGE

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.

As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.